This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zolpidem Reformulation

SELLAS Life Sciences Group

Drug Names(s): zolpidem

Description: The compound is a re-formulation of zolpidem using Catalent’s OSDrC OptiDose drug delivery technology.

Deal Structure: Catalent and Sellas
In December 2014, Catalent Pharma Solutions announced that it had reached an exclusive development and licensing agreement with SELLAS to support the development and therapeutic reprofiling of zolpidem using Catalents OSDrC OptiDose drug delivery technology. Financial details were not disclosed.

Partners: Catalent, Inc

Zolpidem Reformulation News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug